





GAUCHER DISEASE TYPE 3 AND IGA VASCULITIS: A CASE REPORT

Gabriela Festugato Maranhão¹ (e-mail: gmaranhao@hcpa.edu.br); Lucas Ferreira Teixeira¹; Gabriela Ponte de Mattos²; Giovanna Jost Tibolla¹; Dévora Natalia Randon³; Fabiano Poswar⁴; Alicia Dorneles Dornelles^{1,5}; Sandra Helena Machado^{1,5}; François Maillot⁶; Ida Vanessa Doederlein Schwartz^{1,3,4,7}

¹School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil; ²School of Medicine, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil; ³Postgraduate Program in Genetics and Molecular Biology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil; ⁴Department of Genetics, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; ⁵Department of Pediatrics, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; ⁶Department of Internal Medicine, University of Tours, France; ⁷InRaras, National Institute of Science and Technology in Rare Diseases, Porto Alegre, Rio Grande do Sul, Brazil.

INTRODUCTION:

Gaucher Disease (GD) is a lysosomal disorder caused by biallelic pathogenic variants in the GBA1 gene and can course dysregulation. with immune Three phenotypes have been described, and GD type 3 (GD3) is associated with chronic visceral and neurological damage. IgA vasculitis (IgAV) is a kind of immune dysregulation characterized as a non thrombocytopenic vasculitis associated with purpura, arthralgia and IgA1 immune deposition at vessel walls. Our objective is to relate the case of a 4.3-year-old male patient diagnosed with GD3 who had a benign course of IgA vasculitis.

CASE REPORT:

born The patient was to nonа consanguineous couple and diagnosed with GD3 at 1.8 years old due to hepatosplenomegaly, neurological impairment and strabismus. He is homozygous for the pathogenic variant c.1448T>C; p.Leu483Pro (L444P), with a a GCase activity at 1.3 nmol/h/mg protein in leukocytes (Reference value, i.e. RV, 10-45) at the time of diagnosis. He receives biweekly imiglucerase infusions of 60 IU/kg and remains stable. At the age of 4.3 years old, the patient seeked medical assistance after a week-long history of dry cough, bilateral joint pain in the knees and diffuse purpuric skin lesions in abdomen and limbs (see figures 1.A and 1.B). Blood tests at admission showed an increase in Immunoglobulin A (IgA) and C- reactive protein - 503 mg/dL (RV 21-291) and 27.1 mg/L (RV<5), respectively. There was no thrombocytopenia (platelet count was 293,000/µL, with RV>120,000/µL) nor renal function alteration (no hematuria nor proteinuria). The clinical picture along with highly increased plasma **IgA** was suggestive (IgAV) of IgA vasculitis diagnosis. The patient received symptomatic care, and evolved to complete resolution of symptoms.

DISCUSSION:

This case is illustrative of the benign course of IgAV in a GD3 patient, showing that even a GD3 patient who had the disease controlled by ERT could develop transient immune related alterations.

CONCLUSIONS:

This is the first report of these conditions overlap in literature to our knowledge. GD3 may be associated with the arthralgia and purpuric lesions.



